Aptose Biosciences (NASDAQ:APTO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a research note on Tuesday, December 10th.

Aptose Biosciences Price Performance

APTO stock opened at $0.25 on Monday. Aptose Biosciences has a one year low of $0.13 and a one year high of $2.68. The stock has a market cap of $15.05 million, a price-to-earnings ratio of -0.08 and a beta of 1.06. The company has a fifty day moving average price of $0.29 and a two-hundred day moving average price of $0.46.

Institutional Trading of Aptose Biosciences

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 401,750 shares of the biotechnology company’s stock after acquiring an additional 167,282 shares during the quarter. Sigma Planning Corp owned approximately 2.22% of Aptose Biosciences worth $165,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.